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Background
Disorders that irremediably affect fetuses make early stage
therapies desirable. X-linked hypohidrotic ectodermal dys-
plasia (XLHED), the most common inherited disorder of
ectoderm development affecting the skin and its
appendages, glands, and teeth, is caused by a lack of the
signaling molecule ectodysplasin A1 (EDA1). In the Tabby
XLHED mouse model, repeated intravenous administra-
tion of EDA1 to pregnant mice has been shown to correct
the developmental abnormalities in the offspring. Maternal
drug administration, however, exposes mothers to poten-
tial drug toxicity and is limited by the variability in trans-
placental drug delivery. Alternative approaches to fetal
treatment should entail low risk drug delivery with repro-
ducible pharmacokinetics. We hypothesized that a single
injection of an EDA1 replacement molecule into the
amniotic fluid could allow sustained drug exposure at
levels sufficient for correction of XLHED.
Materials and methods
A human IgG1:EDA1 fusion protein, EDI200, was tested
for its stability in human amniotic fluid using a receptor-
binding ELISA. It was injected into amniotic sacs of wild-
type mice to evaluate fetal drug uptake and pharmacoki-
netics, and administered to Tabby mouse fetuses at doses
between 1 and 100 µg/g fetal weight. Phenotypic correc-
tion was assessed.
Results
EDI200 was demonstrated to be stable in amniotic fluid at
37°C for at least one week. Intra-amniotic administration
of the highest dose resulted in substantial fetal uptake
with mean serum levels of 9.0 and 1.2 µg/ml at 6 and 96
hours, respectively. Maternal serum levels remained <0.1
µg/ml. In Tabby mice, a single intra-amniotic EDI200
injection at day 15 of gestation restored normal ectoderm
development in a dose-dependent manner. Doses of
10 μg/g fetal weight or above led to complete phenotypic
correction of skin appendages, eccrine sweat glands, eye
lids, and teeth. No adverse effects of the treatment were
detected during an observation period of one year.
Conclusions
Intra-amniotic protein application may lead to rapid and
continuous fetal uptake, sustained serum levels, and
therapeutic efficacy comparable with repeated maternal
injection. It allows prenatal drug targeting with minimal
maternal exposure and may, thus, represent a novel
paradigm for treatment of disorders in early human
development.
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